Nuclear medicine communications · 2026
PET-derived metabolic-immunonutritional SUVmax-lactate dehydrogenase-albumin-lymphocyte index for survival prediction in human epidermal growth factor receptor 2-positive metastatic breast cancer receiving pertuzumab-based therapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Eniseler Emine Bihter, Ekinci Ferhat, Şahbazlar Mustafa, Erdoğan Atike Pinar
Аннотация
OBJECTIVE: To evaluate the prognostic value of the PET-derived SUVmax-lactate dehydrogenase-albumin-lymphocyte (SUV-LAL) index in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer treated with pertuzumab.
METHODS: This retrospective single-center study included patients with HER2-positive metastatic breast cancer treated with pertuzumab-containing regimens between January 2018 and October 2025. Baseline clinical, pathological, laboratory, and 18F-fluorodeoxyglucose PET/computed tomography data were retrospectively collected. The SUV-LAL index was calculated as (primary tumor maximum standardized uptake value × lactate dehydrogenase)/(albumin × absolute lymphocyte count). Overall survival (OS) and progression-free survival (PFS) were evaluated using Cox proportional hazards regression analyses. Kaplan-Meier survival analysis, receiver operating characteristic (ROC) analysis, and time-dependent ROC analyses were performed to assess prognostic performance.
RESULTS: A total of 80 patients were included, of whom 36 (45.0%) died during follow-up. The SUV-LAL index remained an independent prognostic factor for OS in multivariate analysis [hazard ratio = 1.755, 95% confidence interval (CI) = 1.053-2.927; P = 0.031], together with the number of pertuzumab cycles (hazard ratio = 0.921, 95% CI = 0.872-0.972; P = 0.003). Patients with a high SUV-LAL index had significantly shorter OS and PFS than those with a low SUV-LAL index (log-rank P < 0.001 and P = 0.002, respectively). ROC analysis yielded an area under the curve (AUC) of 0.760. Compared with its individual components, the SUV-LAL index showed the strongest association with OS in univariate Cox regression analysis and achieved the highest 1-year time-dependent AUC (0.735), while maintaining acceptable prognostic performance at 3 years (AUC = 0.705).
CONCLUSION: The PET-derived SUV-LAL index independently predicts OS in HER2-positive metastatic breast cancer treated with pertuzumab.
METHODS: This retrospective single-center study included patients with HER2-positive metastatic breast cancer treated with pertuzumab-containing regimens between January 2018 and October 2025. Baseline clinical, pathological, laboratory, and 18F-fluorodeoxyglucose PET/computed tomography data were retrospectively collected. The SUV-LAL index was calculated as (primary tumor maximum standardized uptake value × lactate dehydrogenase)/(albumin × absolute lymphocyte count). Overall survival (OS) and progression-free survival (PFS) were evaluated using Cox proportional hazards regression analyses. Kaplan-Meier survival analysis, receiver operating characteristic (ROC) analysis, and time-dependent ROC analyses were performed to assess prognostic performance.
RESULTS: A total of 80 patients were included, of whom 36 (45.0%) died during follow-up. The SUV-LAL index remained an independent prognostic factor for OS in multivariate analysis [hazard ratio = 1.755, 95% confidence interval (CI) = 1.053-2.927; P = 0.031], together with the number of pertuzumab cycles (hazard ratio = 0.921, 95% CI = 0.872-0.972; P = 0.003). Patients with a high SUV-LAL index had significantly shorter OS and PFS than those with a low SUV-LAL index (log-rank P < 0.001 and P = 0.002, respectively). ROC analysis yielded an area under the curve (AUC) of 0.760. Compared with its individual components, the SUV-LAL index showed the strongest association with OS in univariate Cox regression analysis and achieved the highest 1-year time-dependent AUC (0.735), while maintaining acceptable prognostic performance at 3 years (AUC = 0.705).
CONCLUSION: The PET-derived SUV-LAL index independently predicts OS in HER2-positive metastatic breast cancer treated with pertuzumab.